Good news could be just around the corner for two drugmakers not named Novo Nordisk.
Vertex is broadening its portfolio.
/CNW/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and TreeFrog Therapeutics today announced that Vertex has obtained an exclusive license to...
And that's just part of the interesting news for investors to dig into.
Could Vertex's growth story continue?
These stocks could be near major inflection points.
While Ark Invest scoops up Tesla, these three Cathie Wood picks have higher analyst ratings than the struggling EV leader.
These stocks probably won't be getting much cheaper.
Low risk and high-reward potential? These stocks could offer both.
Does this pharma stock have the potential to turn a $25,000 investment into seven figures or more?